[Left laparoscopic lobectomy]. / Lobectomie stânga pe cale laparoscopica pentru hepatocarcinom dezvoltat pe ficat non-cirotic--prezentare de caz.

The authors present a case of a 61-year-old patient diagnosed with a hepatic tumor located in the second segment with expression on the anterior (diaphragmatic) side. The diagnosis and treatment applied in this case are presented. The specific feature was the surgical intervention because it was performed a left laparoscopic lobectomy using the LigaSure Atlas sealer. The short hospitalization period and quick recovery make this method an efficient one, with a wide application. Laparoscopic surgery started with a cholecystectomy which was performed by Mouret in 1987. Since then it knew a continuous development with progressive extension of this type of approach to almost all of the digestive tract organs, cavitary as well as parenchymal organs like liver or spleen. Second and third bisegmentectomy was made for the first time in 1996 by Azagra. The segments II, III, IVb, V and VI are the most frequently resected in hepatic laparoscopic surgery. Surgeons are more interested in left hepatic lobe diseases because of the anatomy which makes the approach of the biliary and blood vessels easier. Lately we assist to an increase of hepatic cancer incidence, primary or secondary; therefore we consider necessary the development of hepatic laparoscopic surgical techniques.

[TIVA-TCI (Total IntraVenous Anesthesia-Target Controlled Infusion) versus isoflurane anesthesia for laparoscopic cholecystectomy. Postoperative nausea and vomiting, and patient satisfaction]. / TIVA-tCI vs. anestezia inhalatorie pentru colecistectomia laparoscopica. Incidenta sindromului emetic postoperator si satisfactia pacientilor.

UNLABELLED: Numerous studies have shown that TIVA is followed by a significant reduction in the incidence of PONV in day-case surgery, including laparoscopic cholecystectomy, where the incidence of PONV can reach 70% according to some studies. TCI is the TIVA technique that maintain a constant plasma concentration due to pharmacokynetic models incorporated in TCI device that inject the anesthetic agent. Besides implementing TIVA-TCI in clinical practice in Romania, our study was designed to evaluate the impact of TIVA-TCI on postoperative outcome and our patient satisfaction after laparoscopic cholecystectomy. PATIENTS AND METHODS: After informed consent, 70 patients ASAI/II undergoing laparoscopic cholecystectomy were randomized in 2 equal study groups: group 1 (n = 35) included patients with TIVA-TCI with propofol (Cpi = 4 microg/ml) and remifentanil, and group 2 (n = 35) were patients undergoing Isoflurane anesthesia. In both groups propofol was administered during induction and remifentanil followed the same protocol: 0.5 microg/kg/min in the first minute during induction, followed by 0.25 microg/kg/min. This infusion was modified by 0.05 microg/kg/min steps according to analgesic needs. PONV (evaluated as both incidence and number of episodes), severity of pain and patient satisfaction score IOWA were compared between study groups. RESULTS: Both the incidence of PONV (p = 0.03) and the number of episodes/24 h/patients (p = 0.01) were significantly lower in TIVA-TCI group, while there was no significant difference in opioid requirements in study groups (p = 0.21). Patients IOWA satisfaction score at 24 hours postoperatively was significantly higher in TIVA-TCI groups (p = 0.0001). CONCLUSIONS: Compared with Isoflurane, TIVA-TCI was followed by significantly lower incidence of PONV and significantly greater patients satisfaction.